

1 PATIENT INFORMATION Patient Name: _____ Phone: _____ Address: _____ City: _____ State: _____ Zip: _____ MRN #: _____ DOB: _____ Drug Allergies: _____	2 PRESCRIBER INFORMATION Prescriber's Name: _____ DEA#: _____ NPI: _____ Clinic/Facility Name: _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____
3 Instructions to Provider All orders with ✓ will be placed unless otherwise noted. Please fax completed order form to 844-785-3104. For drug prior authorization, call 1-888-767-4670 or visit https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/preservice .	
4 CLINICAL INFORMATION Diagnosis (ICD-10 code): _____ Date of Last Dose: _____	
5 BEVACIZUMAB BIOSIMILAR PRESCRIPTION INFORMATION Patient will receive bevacizumab-awwb (MVASI™) unless otherwise specified: _____ First Dose: ☐ No ☐ Yes, first dose must be given in Infusion Center Weight: _____ kg Date Recorded: _____ <u>Bevacizumab-awwb (Mvasi™)</u> Route: Intravenous ✓ Dose: _____ mg/Kg [maintenance] (= _____ mg) in 0.9% Sodium Chloride IV infusion Frequency: Every _____ days until end date of _____ Infusion Access: ☐ PIV ☐ CVAD ☐ Other: _____ Patient's Current Infusion Pharmacy: _____ Infusion Reaction Medications & Supplies ✓ Hydrocortisone sodium succinate injectable 100 mg IV Sig: Once PRN for hypersensitivity ✓ Epinephrine Auto-Injector ☐ 0.15mg ☐ 0.3mg QTY: 2 Sig: Inject into lateral thigh muscle for severe allergic reaction. Seek medical attention after use. ✓ Sodium Chloride 0.9% IV Flush: Flush 10 ml IV before/after medication administration or as needed for line maintenance ✓ Diphenhydramine injectable 25 mg IV Sig: Once PRN, may repeat x1 for urticaria, pruritis, shortness of breath ✓ Sodium Chloride 0.9% IV 250 ml Bag Sig: Once PRN for anaphylaxis Labs /Special Instructions/Pre-Meds: ☐ Urine analysis prior to each infusion _____	
Infusion Protocol: - Infuse per manufacturer guidelines - Monitor vital signs (Temp, BP, HR, RR) every 15 minutes x 4; then every 30 minutes x2; then every 60 minutes until completion of infusion - Hold infusion if BP > 160/100 and re-check - If repeated BP > 160/100, do not proceed with infusion and notify pharmacy - Documentation must include: - Start and end time of infusion - All rate changes, vital signs, including initial and final set - Patient response	- Observe patient for signs of infusion rate-related adverse reactions: - Blood pressure changes, increased pulse rate - Fever, chills - Headache - Chest, back or hip pain - Dyspnea - Mild erythema
6 PHYSICIAN SIGNATURE REQUIRED	
X _____ SUBSTITUTION PERMITTED (Date)	X _____ DISPENSE AS WRITTEN (Date)